Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ESPR -- Ignore unavailable to you. Want to Upgrade?

To: StockDoc who wrote (3)	5/2/2001 12:33:56 PM
From: keokalani'nui	Read Replies (3) \| Respond to of 16

Wednesday May 2, 1:26 am Eastern Time Press Release SOURCE: Global News Network Esperion's Apo A-I Milano Protein: Leading a Revolution Against Heart Disease LONDON, May 2 /PRNewswire/ -- This is a Global News Network Report on Esperion Therapeutics (Nasdaq: ESPR - news). Global News Network is currently doing a series of reports on companies with emerging technologies, which have the potential of having a revolutionary impact on the global community and the global economy. This report is available in English, French, Spanish, German, Chinese, Portuguese, Japanese, Hindi and Italian, for international distribution. The following is a Global News Network special report on Esperion Therapeutics. Over twenty-five years ago in Milan, Italy, two scientists discovered a group of Italian people in Northern Italy in their 80's and 90's with extremely healthy coronary arteries, despite the fact they were indulging in extremely high-risk activities such as high-fat diets and routine smoking. Scientists have been able to isolate the trigger for these people's exceptional cardiac health. It is a protein called the Apolipoprotein A-I. A company by the name of Esperion Therapeutics is now testing the synthetic form of Apolipoprotein A-I -- referred to as the Apo A-I Milano protein. Dr. Roger S. Newton leads the Esperion research team in the United States and in Esperion's facility in Solna, Sweden. Dr. Newton, along with three of his colleagues at Esperion, have extensive experience in drug development due to their work on cholesterol lowering drugs at Parke-Davis. One of these drugs, Lipitor®, has had one of the most successful product launches in pharmaceutical history -- with estimated sales of six billion dollars by 2002; and, although drugs such as Lipitor® have been shown to slow the process of arteriosclerosis, they generally do nothing to cure arteriosclerosis. As a result, despite the expense of these drugs, patients often have to endure the rigors of angioplasty and open-heart surgery. Cardiovascular disease is the largest killer of American men and women and over 15 billion dollars are spent every year treating the disease. Curing this plague would not only be merciful but astronomically profitable. Approximately 20% of the world's population has some form of heart disease. At Cedars Sinai Medical Center in Los Angeles, Esperion's Apo A-I Milano protein has already been shown in preclinical studies in animals to not only stop the progression of arteriosclerosis, but to actually reverse the process, and, as of March 29, 2001, Esperion completed their phase I study of the Apo A-I Milano protein in normal human volunteers with positive results and will begin phase II trials in the next few months. Having received over 21 million dollars in research funding, Esperion is now in the process of optimizing clinical and regulatory strategies to shorten time to market. (Esperion's Apo A-I Milano protein has been diligently protected with a series of worldwide patents.) With Dr. Newton, his colleagues, and an international group of drug development executives and advisors, Esperion consists of some of the best research specialists in molecular, cardiovascular, pharmaceutical and genetic research. Esperion's Apo A-I Milano protein holds tremendous promise for the hundreds of millions of people who suffer from heart disease. You may access this company's website at esperion.com . (Esperion trades on the NASDAQ stock exchange under the symbol ESPR). Global News Network Company Statement: This report is an editorial statement of publicly available information. Global News Network is a news dissemination service and does not purchase or sell or own any stocks in any publicly traded companies as a matter of company policy. Global News Network does not accept compensation from nor is it affiliated with companies featured in Global News Network Reports. This report is not a solicitation to buy or sell stocks. Anyone or any company doing work for or associated with Global News Network in any way may or may not own stocks in any publicly traded companies including the company or companies featured in this article. Any statements looking into the future in this report would be subject to the risks and uncertainties of future events. Global News Network is currently preparing a website which will be dedicated to new and developing technologies and the companies who develop and create these technologies. Revenues will be generated by traditional advertisement, affiliate and membership fees. The website address will be www.GNNglobalnews.com/ . This is not currently a working website. The website is scheduled for a January 1, 2002, premiere. SOURCE: Global News Network